Glenda M. Halliday

96.4k total citations · 14 hit papers
661 papers, 51.2k citations indexed

About

Glenda M. Halliday is a scholar working on Neurology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Glenda M. Halliday has authored 661 papers receiving a total of 51.2k indexed citations (citations by other indexed papers that have themselves been cited), including 392 papers in Neurology, 224 papers in Physiology and 163 papers in Cellular and Molecular Neuroscience. Recurrent topics in Glenda M. Halliday's work include Parkinson's Disease Mechanisms and Treatments (312 papers), Alzheimer's disease research and treatments (202 papers) and Neurological disorders and treatments (122 papers). Glenda M. Halliday is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (312 papers), Alzheimer's disease research and treatments (202 papers) and Neurological disorders and treatments (122 papers). Glenda M. Halliday collaborates with scholars based in Australia, United States and United Kingdom. Glenda M. Halliday's co-authors include Jillian J. Kril, Anthony E. Lang, Werner Poewe, José Á. Obeso, John G. Morris, Charles H. Adler, M. A. Hely, C. Warren Olanow, Klaus Seppi and Patrik Brundin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Glenda M. Halliday

641 papers receiving 50.3k citations

Hit Papers

MDS clinical diagnostic... 1987 2026 2000 2013 2015 2017 2008 2013 2015 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MDS clinical diagnostic criteria for Parkinson's disease
    2015 4.8k citations Ronald B. Postuma, Daniela Berg et al. Movement Disorders profile →
  2. Parkinson disease
    2017 3.3k citations Werner Poewe, Klaus Seppi et al. Nature Reviews Disease Primers profile →
  3. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
    2008 1.6k citations Glenda M. Halliday et al. Movement Disorders profile →
  4. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
    2013 892 citations C. Warren Olanow, Glenda M. Halliday et al. profile →
  5. MDS research criteria for prodromal Parkinson's disease
    2015 876 citations Daniela Berg, Ronald B. Postuma et al. Movement Disorders profile →
  6. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity
    1987 819 citations Glenda M. Halliday et al. profile →
  7. Parkinson disease-associated cognitive impairment
    2021 778 citations Glenda M. Halliday et al. Nature Reviews Disease Primers profile →
  8. Selective neuronal vulnerability in Parkinson disease
    2017 726 citations D. James Surmeier, José Á. Obeso et al. profile →
  9. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
    2009 698 citations Thomas Gasser, Glenda M. Halliday et al. profile →
  10. Missing pieces in the Parkinson's disease puzzle
    2010 569 citations José Á. Obeso, Glenda M. Halliday et al. profile →
  11. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism
    2015 542 citations Stanley B. Prusiner, Amanda L. Woerman et al. Proceedings of the National Academy of Sciences profile →
  12. Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation
    2001 536 citations Glenda M. Halliday et al. profile →
  13. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
    2014 382 citations Woojin S. Kim, Antony A. Cooper et al. profile →
  14. Multiple system atrophy
    2022 138 citations Werner Poewe, Glenda M. Halliday et al. Nature Reviews Disease Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Glenda M. Halliday Australia 104 30.2k 13.7k 13.4k 10.6k 8.9k 661 51.2k
K. A. Jellinger Austria 111 21.7k 0.7× 11.2k 0.8× 13.4k 1.0× 9.1k 0.9× 9.7k 1.1× 1.0k 48.6k
Andrew J. Lees United Kingdom 129 56.1k 1.9× 21.1k 1.5× 11.3k 0.8× 10.3k 1.0× 10.9k 1.2× 733 74.2k
Kelly Del Tredici Germany 68 20.5k 0.7× 8.3k 0.6× 11.3k 0.8× 6.2k 0.6× 6.6k 0.7× 145 33.3k
Joseph Jankovic United States 122 45.1k 1.5× 19.4k 1.4× 6.7k 0.5× 6.4k 0.6× 5.9k 0.7× 815 59.9k
Anthony E. Lang Canada 129 57.7k 1.9× 25.0k 1.8× 8.1k 0.6× 8.6k 0.8× 10.8k 1.2× 905 77.2k
Yves Agid France 120 31.6k 1.0× 25.5k 1.9× 6.4k 0.5× 12.9k 1.2× 8.3k 0.9× 608 55.1k
David J. Brooks United Kingdom 127 31.5k 1.0× 19.9k 1.5× 9.9k 0.7× 8.5k 0.8× 10.6k 1.2× 747 61.8k
Maiken Nedergaard United States 138 14.5k 0.5× 33.9k 2.5× 9.9k 0.7× 16.4k 1.6× 16.2k 1.8× 406 66.8k
Heiko Braak Germany 107 26.6k 0.9× 16.5k 1.2× 32.3k 2.4× 14.3k 1.4× 13.8k 1.6× 362 68.5k
Thomas Gasser Germany 93 21.1k 0.7× 8.8k 0.6× 5.6k 0.4× 7.8k 0.7× 4.9k 0.6× 544 35.4k

Countries citing papers authored by Glenda M. Halliday

Since Specialization
Citations

This map shows the geographic impact of Glenda M. Halliday's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Glenda M. Halliday with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Glenda M. Halliday more than expected).

Fields of papers citing papers by Glenda M. Halliday

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Glenda M. Halliday. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Glenda M. Halliday. The network helps show where Glenda M. Halliday may publish in the future.

Co-authorship network of co-authors of Glenda M. Halliday

This figure shows the co-authorship network connecting the top 25 collaborators of Glenda M. Halliday. A scholar is included among the top collaborators of Glenda M. Halliday based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Glenda M. Halliday. Glenda M. Halliday is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nilsson, Sandra, Claire E. Shepherd, Ian Zammit, et al.. (2025). Number of Carbons Is a Critical Parameter for Accumulation of Per- and Polyfluoroalkyl Substances in the Human Brain. Environmental Science & Technology. 59(7). 3366–3375. 2 indexed citations
2.
Hunt, Cameron J., Clare L. Parish, Laura H. Jacobson, et al.. (2025). Evidence of COMT dysfunction in the olfactory bulb in Parkinson’s disease. Acta Neuropathologica. 149(1). 21–21.
3.
Lewis, Simon J.G., Carolyn M. Sue, Antony A. Cooper, & Glenda M. Halliday. (2025). Future is now: an Australasian perspective on disease-modifying trials in Parkinson’s and prodromal disease. BMJ Neurology Open. 7(1). e001070–e001070.
4.
Burré, Jacqueline, Robert H. Edwards, Glenda M. Halliday, et al.. (2024). Research Priorities on the Role of α‐ Synuclein in Parkinson's Disease Pathogenesis. Movement Disorders. 39(10). 1663–1678. 16 indexed citations
5.
Galper, Jasmin, Giorgia Mori, Gordon McDonald, et al.. (2024). Prediction of motor and non-motor Parkinson’s disease symptoms using serum lipidomics and machine learning: a 2-year study. npj Parkinson s Disease. 10(1). 123–123. 5 indexed citations
6.
Roudeau, Stéphane, Benjamin G. Trist, Asunción Carmona, et al.. (2021). Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological Workflow. Analytical Chemistry. 93(32). 11108–11115. 5 indexed citations
7.
Fu, YuHong, et al.. (2021). Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. Movement Disorders. 36(9). 2085–2093. 29 indexed citations
8.
Gabery, Sanaz, Rebekah M. Ahmed, Jashelle Caga, et al.. (2021). Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology. 47(7). 979–989. 38 indexed citations
9.
Phan, Katherine, Ying He, YuHong Fu, et al.. (2021). Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. SHILAP Revista de lepidopterología. 1(1). 22 indexed citations
10.
Newman, Morgan, Seyyed Hani Moussavi Nik, Greg T. Sutherland, et al.. (2020). Accelerated loss of hypoxia response in zebrafish with familial Alzheimer’s disease-like mutation of presenilin 1. Human Molecular Genetics. 29(14). 2379–2394. 11 indexed citations
11.
Phan, Katherine, Ying He, Russell Pickford, et al.. (2020). Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Scientific Reports. 10(1). 3640–3640. 49 indexed citations
12.
Strohäker, Timo, Byung Chul Jung, Shu-Hao Liou, et al.. (2019). Structural heterogeneity of α-synuclein fibrils amplified from patient brain extracts. Nature Communications. 10(1). 5535–5535. 155 indexed citations
13.
Poewe, Werner, Klaus Seppi, Caroline M. Tanner, et al.. (2017). Parkinson disease. Nature Reviews Disease Primers. 3(1). 17013–17013. 3343 indexed citations breakdown →
14.
Prusiner, Stanley B., Amanda L. Woerman, Daniel A. Mordes, et al.. (2015). Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences. 112(38). E5308–17. 542 indexed citations breakdown →
15.
Berg, Daniela, Ronald B. Postuma, Bastiaan R. Bloem, et al.. (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders. 29(4). 454–462. 341 indexed citations
16.
Wong, Jenny, Brett Garner, Glenda M. Halliday, & John B. Kwok. (2012). Srp20 regulates TrkB pre‐mRNA splicing to generate TrkB‐Shc transcripts with implications for Alzheimer’s disease. Journal of Neurochemistry. 123(1). 159–171. 31 indexed citations
17.
Halliday, Glenda M., et al.. (2008). Neuropathologic correlates of white matter hyperintensities. Neurology. 71(11). 804–811. 267 indexed citations
18.
Dedov, Vadim N., et al.. (2007). Lipid content determines aggregation of neuromelanin granules in vitro. PubMed. 35–38. 4 indexed citations
19.
Piguet, Olivier, Hayley Bennett, Louise M. Waite, et al.. (2006). Preserved Cognition and Functional Independence after a Large Right Posterior Cerebral Artery Infarct: Longitudinal Clinical and Neuropathological Findings. Neurocase. 12(2). 81–90. 4 indexed citations
20.
Halliday, Glenda M., et al.. (1994). Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica. 87(2). 174–186. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. A. Jellinger Breakdown of academic impact, for papers by Andrew J. Lees Breakdown of academic impact, for papers by Kelly Del Tredici Breakdown of academic impact, for papers by Joseph Jankovic Breakdown of academic impact, for papers by Anthony E. Lang Breakdown of academic impact, for papers by Yves Agid Breakdown of academic impact, for papers by David J. Brooks Breakdown of academic impact, for papers by Maiken Nedergaard Breakdown of academic impact, for papers by Heiko Braak Breakdown of academic impact, for papers by Thomas Gasser
Rankless by CCL
2026